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Side effectsAbstract The behavioral responses exerted by spinal administration of the opioid-neurotensin hybrid
peptide, PK23, were studied in adult male rats. The antinociceptive effect upon exposure to a thermal
stimulus, as well as tolerance development, was assessed in an acute pain model. The PK23 chimera
at a dose of 10 nmol/rat produced a potent pain-relieving effect, especially after its intrathecal adminis-
tration. Compared with intrathecal morphine, this novel compound was found to possess a favourable side
effect profile characterized by a reduced scratch reflex, delayed development of analgesic tolerance or an
absence of motor impairments when given in the same manner, though some animals died following bar-
rel rotation as a result of its i.c.v. administration (in particular at doses higher than 10 nmol/rat). Nonethe-
less, these results suggest the potential use of hybrid compounds encompassing both opioid and
neurotensin structural fragments in pain management. This highlights the enormous potential of synthetic
neurotensin analogues as promising future analgesics.
ª 2020 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical
Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Opioid-based hybrid structures have been proposed as a putative
valuable alternative to the use of strong opioids administered
alone or in combination with other drugs. The development of
such novel compounds for pain management is directed by the
objective of reducing possible adverse side effects as well as to
minimize the risk for drug interactions. Indeed, prolonged use of
opioids that are considered the most potent and effective analge-
sics1 to date is commonly accompanied by burdensome side ef-
fects (e.g., constipation, vomiting, nausea, tolerance, physical
dependence, itch, motor impairment, and an increased risk of
respiratory depression2e7). Therefore, much effort is dedicated to
the discovery of innovative drugs that would retain their opioid
activity, but were less likely to cause severe adverse effects that
require medical intervention.
In our recent work, we presented several hybrid compounds
that encompassed two pharmacologically distinct pharmacophores
confined in one molecular scaffold, which resulted in potent drug-
like molecules with dual activity8,9. These two chimeras (i.e.,
AA3052 and [Ile9]PK20) were identified as promising pain killers,
devoid of several opioid-induced side effects8. This illustrates how
administration of two active entities joined chemically into one
molecule may significantly improve physicochemical and phar-
macokinetic properties of individual molecules. This enables the
drug to reach its specific target without modifying other properly
functioning processes in the body10,11. Additionally, apart from an
improved biological activity, such drugs could also prove useful
for the treatment of other comorbidities12e14.
In the present study, we focused on a novel hybrid that com-
bines opioid and neurotensin (NT)-like fragments. Of note, neu-
rotensin was previously documented for its opioid-independent
role in pain modulation15e17. Also, by inhibiting dopamine
release18, NT may prove efficient in modulating the rewarding
effect of opioids. Herein presented is an opioid-derived hybrid
peptide codenamed PK23, the third compound of the series
designed by our group that encompasses an NT pharmacophore.
This structure, however, differs from both PK20 or [Ile9]PK20 by
i) the D-amino acid residue located in the second position from the
N-terminal, as well as ii) the presence of unnatural amino acids in
the first and ninth positions. This bivalent drug lacks both the
dimethyl tyrosine and tert-leucine present in PK2012 that couldresult either in a lower m-opioid receptor binding affinity or
reduced plasma stability. Additionally, incorporation of polar
amino acid residues in the chain, particularly alanine, may result
in lower bloodebrain barrier (BBB) permeability19. We herein
investigated how these modifications impact on the biological
activity of this new hybrid compound. Apart from preliminary
in vitro studies, we evaluated the antinociceptive properties of
PK23 upon various delivery routes and examined some possible
undesirable side effects arising from its repeated administration.
2. Materials and methods
2.1. Drugs and chemicals
The opioideNT hybrid peptidedPK23 (Tyr-D-Ala-Phe-Phe-Lys-
Lys-Pro-Phe-Ile-Leu-OH) was designed and prepared at the
Department of Neuropeptides of the Mossakowski Medical
Research Centre PAS (Warsaw, Poland) by manual solid-phase
peptide synthesis using N-fluorenylmethoxycarbonyl (Fmoc)
chemistry. Morphine was obtained from Polfa (Warsaw, Poland)
and similarly to the chimera tested, was dissolved in saline. NT as
well as naltrexone, an opioid receptor antagonist together with SR
48692 and NTRC 824, NTS1 and NTS2 receptor selective an-
tagonists, respectively, were purchased from Tocris Bioscience
(Germany). The anaesthetic drugs ketamine and xylazine were
purchased from Biowet (Pulawy, Poland) while isoflurane was
obtained from Baxter (Cracow, Poland).
Guanosine-5-[g-35S]-triphosphate (1000 Ci/mmol, [35S]
GTPgS) was purchased from Hartmann Analytic (Braunschweig,
Germany), whereas [3H]DAMGOwas purchased from PerkinElmer
(Waltham, MA, USA). EDTA, bovine serum albumin (BSA),
polyethylenimine (PEI), tris(hydroxymethyl)amino-methane (Tris),
guanosine 50-diphosphate (GDP), unlabeled GTPgS, and peptidase
inhibitorsdbestatin, bacitracin and phosphoramidon were pur-
chased from SigmaeAldrich (St. Louis, MO, USA).
2.2. Animals
Adult male Wistar rats (225e250 g body weight) were provided
by the Animal facility of the Medical University of Warsaw. The
animals were housed under standard laboratory conditions (at
ambient temperature of 22  2 C, 12e12 h lightedark cycle).
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cages with soft bedding, food and water available at all times,
except during the course of the experiments.
The experimental protocols for animal usage were approved by
the II Local Commission for the Care and Use of Laboratory
Animals for Experimental Procedures in Warsaw (Permit
numbers: 27/2015 and 167/2016) and adhered to guidelines pub-
lished in the European directive 2010/63/EU on the protection of
animals used for scientific purposes.
2.3. Ligand-stimulated functional [35S]GTPgS assay
2.3.1. Cell culture and membrane preparation
2.3.1.1. Opioid receptors. Forebrain membrane fractions were
prepared according to the method previously described by Benyhe
et al20. Briefly, rats were decapitated and the whole brain (without
cerebellum) was quickly removed and homogenized in 30 vol-
umes (mL/g wet mass) of 50 mmol/L Tris-HCl buffer (pH 7.4)
with a Teflon-glass homogenizer. The same procedure was used
for spinal cord specimens. The homogenates were then centri-
fuged at 18,000 rpm (Microfuge 20, Beckman Coulter Life Sci-
ence, Poland) for 20 min at 4 C. The resulting pellets were
resuspended in a fresh 50 mmol/L Tris-HCl buffer (30 volume/
weight) and then incubated for 30 min at 37 C. Subsequently, the
centrifugation step was repeated. The final pellets were resus-
pended in 5 volumes of 50 mmol/L Tris-HCl (pH 7.4) buffer
containing 0.32 mol/L sucrose and stored at 80 C until future
use. For binding assays, membranes were thawed and then
resuspended in 50 mmol/L Tris-HCl (pH 7.4) buffer and centri-
fuged at 18,000 rpm for 20 min at 4 C in order to remove sucrose.
The resulting pellets were suspended in ice-cold TEM buffer
[50 mmol/L Tris-HCl (pH 7.2), 2 mmol/L EDTA, 1 mmol/L
EGTA, 5 mmol/L MgCl2] to obtain a protein concentration of
approx. 40 mg/mL per assay.
2.3.1.2. NTS1 receptors. Transfected CHO cells expressing
the rat NTS121 were grown in MEM alpha medium supplemented
with 10% foetal calf serum, 85 mg/mL streptomycin and 85 U/mL
penicillin. Cultures were maintained at 37 C in a humidified at-
mosphere of 5% CO2e95% air.
2.3.2. GTPgS binding assays for m-opioids receptors
Membrane fractions from rat brain and spinal cord (w10 mg of
protein/tube) were incubated at 30 C for 60 min in Tris-EGTA
buffer (50 mmol/L Tris-HCl, 1 mmol/L EGTA, 3 mmol/L MgCl2,
100 mmol/L NaCl, pH 7.4) containing [35S]GTPgS (0.05 nmol/L)
and increasing concentrations (109 to 105 mol/L) of the com-
pounds tested in the presence of 30 mmol/L GDP in a final volume
of 1 mL. Non-specific binding was determined in the presence of
10 mmol/L unlabeled GTPgS and subtracted from total binding to
determine specific binding. The reaction was initiated by addition
of [35S]GTPgS and terminated by filtrating the samples through
Whatman GF/B glass fiber filters. Filters were washed three times
with ice-cold 50 mmol/L Tris-HCl buffer (pH 7.4) using the
Brandel M24R Cell Harvester, then dried. Bound radioactivity
was detected in an UltimaGold™ scintillation cocktail (Packard,
Meriden, CT, USA). Agonist-induced receptor-mediated G protein
stimulation was expressed as percentage over the specific [35S]
GTPgS binding observed in the absence of ligands (basalactivity). [35S]GTPgS binding assays were performed in duplicate
and all experiments were carried out three times independently.
2.3.3. [35S]GTPgS binding assays for CHO cells stably
expressing the NTS1 receptors
The specific binding of [35S]GTPgS was measured in cell ho-
mogenates as previously described22. Briefly, cell homogenates
(25e50 mg) were resuspended in binding buffer (50 mmol/L
Tris-HCl (pH 7.4) containing 5 mmol/L MgCl2, 1 mmol/L 1e10
phenanthroline, 0.1% BSA, 1 mmol/L GDP, 150 mmol/L NaCl and
1 mmol/L dithiothreitol). The homogenate was incubated for
40 min in the presence of 0.05 nmol/L [35S]GTPgS at 37 C. Non-
specific binding of [35S]GTPgS was measured in the presence of
0.1 mmol/L Gpp(NH)p. Incubation was terminated by addition of
3 mL ice-cold binding buffer and the suspension was immediately
filtered through GF/B glass fibre filters and washed twice with the
same buffer using a 24-channel Brandel Harvester (SEMAT, St
Albans, Hertfordshire, UK). Radioactivity trapped on the filter
was estimated by scintillation counting. Results are expressed as
mentioned above (see Section 2.3.2).
2.4. Surgical procedures performed for further determination of
drug-mediated analgesia
2.4.1. Intracerebroventricular catheterization
For the intracerebroventricular (central, i.c.v.) drug administration,
rats were implanted with cannulas according to the previously
published protocol9. Briefly, rats were deeply anesthetized with a
mixture of ketamine (87 mg/kg, i.p.) and xylazine (13 mg/kg, i.p.).
A longitudinal skin incision was made along the midline to expose
the skull. Polyethylene cannulas (PE 10, Intramedic™ Poly-
ethylene Tubing, ClayeAdams Company, New York, USA;
ID Z 0.28 mm, OD Z 0.61 mm, and 5 cm in length) were
inserted into the right lateral ventricle. The cannula was secured
by dental cement (Ketac™ Cem radiopaque, 3M ESPE, Ger-
many). After surgery, animals were placed in separate cages and
the experiment began on the fifth day after surgery. Animals
showing signs of motor impairment were excluded from the
experiment and immediately euthanized.
2.4.2. Intrathecal catheterization
Intrathecal (spinal, i.t.) administration of test drugs was performed
using a method previously described by Yaksh and Rudy23. Rats
were anaesthetized with a mixture of ketamine/xylaxine as
detailed here above and placed in a stereotaxic head holder. A
silicone catheter (PE 10, Intramedic™ Polyethylene Tubing,
ClayeAdams Company, New York, USA; ID Z 0.28 mm,
OD Z 0.61 mm, and 13 cm in length) was inserted into the
intrathecal space through the atlanto-occipital membrane, posi-
tioning the tip at the L1 spinal level. Dental cement was used to fix
the guide cannula to the skull. After surgery, animals with no
obvious motor deficits were allowed to recover for 4 days before
pharmacological experiments. However, during this time, rats
were habituated to the experimenter in order to minimize stress.
Animals showing paralysis or other signs of motor impairment
after recovering from anaesthesia were immediately euthanized.
After each cannulation (i.c.v. or i.t.) the cannula/catheter
placement was verified by an injection of 5% methylene blue and
further checking for distribution within either the cerebroven-
tricular or spinal subarachnoid space, respectively.
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drug-induced hypotension and respiratory depression
Rats were i.t. catheterized as described in Section 2.4.2. For
measurements of cardiovascular and respiratory parameters, ani-
mals were anesthetized with an intraperitoneal injection of
600 mg/kg urethane and 120 mg/kg alpha-chloralose (Sigma-
eAldrich, Poznan, Poland). The depth of anaesthesia was assessed
by monitoring any changes in blood pressure to a noxious pinch to
the tail. Next, animals were placed in a supine position on a
heating pad so that rectal temperature was kept between 37 and
38 C. Tracheotomy was performed in the neck. A catheter was
inserted into the femoral artery. Cardiovascular and respiratory
responses to i.t. PK23 (10 nmol/rat) injection were examined right
after the end of surgical procedures.
2.6. Drug administration and treatment
2.6.1. Acute pain model
The PK23 hybrid peptide was dissolved in sterile 0.9% NaCl and
brought to room temperature. For single i.t. and i.c.v. injections,
four various dosages of the peptide (0.5, 2, 5 and 10 nmol/rat)
were administered through the catheter at a maximal volume of 10
and 3 mL, respectively. Noteworthy, the dose range used in the
current experiment, in particular for i.t. administration, is similar
to those used in our previous studies8,12, so the impact of amino
acids replacement on drug biological activity could be observed.
For i.p. administration, two doses of 1.8 and 2.7 mmol/rat were
used. Control animals received saline. In order to determine the
involvement of the opioidergic and NTergic systems in analgesia,
animals were pre-treated with an opioid receptor antagonist,
naltrexone (NTX), an NTS1 antagonist SR 48692, or an NTS2
antagonist, NTRC 82424. Each antagonist, except for NTX,
was dissolved in saline with 5% DMSO supplemented with one
drop of Tween 80 (SigmaeAldrich) as vehicle, and injected i.t. at
10 mg/rat, 10 min before PK23 administration. Morphine
(10 nmol/rat, i.t.; dissolved in sterile 0.9% NaCl) was used as a
reference analgesic.
Rats (n Z 5 per group) were intravenously injected with PK23
(1, 2.5 and 5 mg/kg m.c.). Briefly, the rat’s tail was immersed in
hot-water (42 C) for 40e50 s in order to stimulate dilation of the
tail veins. The tail was dried and the test chimera was injected.
Nocifensive responses were measured individually in each animal
in the tail-flick test at selected time intervals for 2 h. Subsequently,
in order to preliminary determine in vivo BBB permeability, brains
were removed for further HPLC studies (HPLC conditions
described in Section 2.9).
2.6.2. Tolerance and cross-tolerance study
In order to evaluate tolerance to analgesic effects of PK23
and morphine, escalating doses of these drugs (0.5, 2, 5 and
10 nmol/rat) were administered intrathecally (i.t.) for 8 consecu-
tive days. Measurements of nociceptive response to thermal
stimuli were conducted daily at 30 min post-injection. On the 1st
and 4th day (or 3rd day in case of morphine-treated group), the
doseeresponse curves were generated and the ED50 values were
calculated to determine the potency of tested drugs.
A state of tolerance was indicated by a progressive decrease in
analgesic effect and an increase in ED50 values due to rightward
shift in the acute doseeresponse curve. For morphine treated
group, doseeresponse curve was generated on the third day of the
experiment due to dramatic decline of analgesic potency in furtherdays (antinociceptive effect was less than 50% MPE at the highest
dose). Additionally, the range of tested doses in tolerance study
was limited by the development of hyperalgesia resulting in lack
of dose-dependent effect in morphine treated group.
The dose of 10 nmol/rat of tested drugs was selected to clearly
present the changes in antinociceptive effect including hyperalgesia
over the 8-day period of administration. Additionally, cross-
tolerance between both drugs was investigated on the 9th day with
a single injection of morphine (10 nmol/rat, i.t.) to the repeated
PK23 group or a single administration of PK23 (10 nmol/rat, i.t.) to
themorphine-treated group. The pain responsewasmeasured on the
same day 30 min post-administration, and presented as MPE (%).
2.6.3. Cardiovascular and respiratory effects
To study any adverse effects of the hybrid on respiration, heart rate
and blood pressure anesthetized rats were injected i.t. with a single
antinociceptive dose of PK23 (10 nmol/rat), and NaCl at interval
of at least 40 min. The effects of PK23 and saline were registered
for 30 min.
2.7. Behavioral experiments
2.7.1. Tail-flick test
The nociceptive threshold was measured in the tail-flick apparatus
(Ugo Basil 37360, Italy). Briefly, the tail was exposed to a
powerful light beam and the tail-flick response latency was
recorded. A 15 s cut-off time was chosen to prevent tissue damage.
Measurements were taken in triplicate at baseline and 15, 30, 60,
90 and 120 min post-injection (acute pain model) or every 24 h
after drug administration (subchronic administration).
2.7.2. Evaluation of motor impairment
We adapted a previous protocol described for this model9. Briefly,
animals were trained to walk on the Rotarod apparatus (model
47700; Ugo Basile S.R.L., Italy) at an accelerating speed of
2e20 rpm (model 47700; Ugo Basile S.R.L., Italy) per 5 min for a
maximal cut-off time of 300 s, according to the method described
by Chu et al.25 Baseline values were recorded for each rat before
i.t. administration of the drug tested or vehicle. Next, animals
were randomly divided into the three following groups: i) group
one received the PK23 chimera (10 nmol/rat), ii) group two
received morphine (10 nmol/rat) and iii) group three was admin-
istered with saline (0.9% NaCl). Rats were placed on the rotating
cylinder and the latency to fall was recorded. Each rat was sub-
jected to three trials, 5 min apart. No injuries were caused by
falling from the apparatus.
2.7.3. Evaluation of scratching and grooming behaviour in rats
The number of scratching and grooming events exhibited by the
animals after i.t. injection of morphine (10 nmol/rat), PK23 (10
nmol/rat) or saline were monitored. Measurements were scored by
individuals who were blinded to the experimental conditions,
observing only one rat at a time. Rats were placed separately in
Plexiglas boxes (18 cm  23 cm  20 cm) and habituated for
30 min. Observation for the morphine, PK23 and control groups
started 2 min after drug administration. The behavioural responses
were scored in 10 min intervals within a 30 min observation
period. Scratching behaviour was defined as short-duration epi-
sodes of back-and-forth scraping across the body surface with the
claws of the hind paw, whereas a facial grooming event was an
episode of head- or face-washing movements with the forepaws.
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respiratory effects in anesthetized rats
Blood pressure and heart rate in rats challenged with i.t. PK23 (10
nmol/rat) were measured via a catheter inserted into the femoral
artery and connected to a BP-2 blood pressure monitor (Columbus
Instruments, Columbus, OH, USA). Tidal volume signals were
recorded with a pneumotachograph head attached to the tracheal
cannula connected with a Research Pneumotach System (RSS 100
HR, Hans Rudolph Inc., Kansas City, MO, USA) and a comput-
erized recording system (KORR Medical Technologies Inc., Salt
Lake City, UT, USA) for measuring respiratory frequency ( f ),
tidal volume (VT) and minute ventilation (VE). The recordings
were registered on an Omnilight 8M36 apparatus (Honeywell,
Tokyo, Japan).
The values of f, VT, VE, mean arterial blood pressure (MAP)
and heart rate (HR) were calculated by averaging the variables
measured for five sequential respiratory cycles just before drug
injection, and at chosen time points of postechallenge phase. The
maximum values were chosen from the computed time points
ranging from 1 to 5 min.
2.9. In vitro plasma stability study
For plasma stability studies of PK23, control rats (n Z 3) were
anaesthetized with isoflurane and whole blood samples were
collected via cardiac puncture into violet BD Vacutainer tubes.
Blood was centrifuged for 4 C for 10 min at 18,000 rpm
(Microfuge 20, Beckman Coulter Life Science, Poland) to remove
the fibrin clot and plasma was carefully transferred into
eppendorf tube using a pipette. Fifty mL of PK23 solution in water
(1000 mg/mL) was added to 400 mL of plasma sample and incu-
bated at 37 C for up to 24 h (incubation times were set to 0, 1, 2,
4, 6, 8, 12 and 24 h). Prior to UHPLC analysis, PK23-enriched
plasma samples (25 mL) were quenched with 200 mL of acetoni-
trile for protein precipitation, vortex mixed for 1 min, kept at 4 C
for 15 min and then centrifuged at 4 C for 15 min at 17,000 rpm.
The resulting supernatants (ca. 100 mL) were transfered into vials
with glass inserts and analyzed by UHPLCeDADeMS.
UHPLCeDADeMS analysis was conducted using a Dionex Ul-
timate 3000RS system coupled with an Amazon SL ion trap mass
spectrometer (Bruker Daltonics, Bremen, Germany). The ion trap
AmazonSL mass spectrometer was equipped with an ESI inter-
face. The eluate was introduced into the ESI interface of the mass
spectrometer without splitting. The parameters for the ESI source
were as follows: nebulizer pressure 40 psi; dry gas flow 9 L/min;
dry temperature 145 C; and capillary voltage 4.5 kV. The analysis
was carried out using scanning from m/z 70 to 2200. Mass spectra
were recorded in negative-ion mode. The separation was carriedTable 1 Pharmacological characterization of morphine, NT and PK
Peptide Potency pEC50SEM (EC50, nmol/L)
Opioid receptor mediated effect NTS1 re
mediated
Brain Spinal cord
Morphine 8.46  0.10 (3.5)25 6.92  0.16 (120) N/A
NT N/A N/A 8.50  0
PK23 6.71  0.51 (197) 5.91  0.25 (1222) 6.95  0out on a Kinetex XB-C18 (150 mm  2.1 mm  1.7 mm, Phe-
nomenex, Torrance, CA, USA) column maintained at 25 C. The
mobile phases were 0.1% HCOOH in water (A) and 0.1%
HCOOH in acetonitrile (B), and elution was conducted with the
following gradient: 0 min, 5% B; 15 min, 50% B; and 20 min,
65% B. The flow rate was 0.3 mL/min, and the sample injection
volume was 5 mL. The UVeVis spectra of the detected com-
pounds were recorded over the 190e450 nm range. The chro-
matogram was recorded at 205 nm. Quantification of PK23 was
performed using a MS detector. Extracted ion chromatograms
(EIC) for all samples at m/z Z 1272 amu were calculated and the
area of the detected peak at ca.12.6 min was measured.
Calibration curves based on the amount injected (ng) versus
peak area were plotted. Linear regression fit was used for the data
obtained. Residual compound concentration in plasma was
calculated. Next, the plot showing the logarithm of the remained
fraction of PK23 vs. incubation time was generated. The linear fit
model was used. The t1/2 was calculated using the slope (b) of the
generate cure according to the following formula: t1/2 Z 0.693/b.
2.10. Statistical analyses
Group size was determined based on power analysis. Additionally,
block randomization method was used in order to allocate animals
into respective treatment groups. The experimenters were all blin-
ded to treatments. Data were analysed with the use of GraphPad
Prism v.5.0 software (GraphPad Software, San Diego, CA, USA,
www.graphpad.com). Figures were generated by the same software,
except for data obtained from binding studies. In this case, experi-
mental data were analysed and graphically processed by the
GraphPad Prism software (version 4.00 for Windows, GraphPad
Software). In binding experiments, displacement curves were fitted
by non-linear regression using the one-site competition fitting op-
tionwith no ligand depletionmodel. Resultswere expressed as EC50
values  SEM (standard error of mean).
Results from behavioral studies were expressed as a percent of
the maximal possible effect (MPE, %) using Eq. (1):
MPE ð%Þ Z ðpdrbrÞ= ðcobrÞ  100 ð1Þ
where pdr, br and co refer to post drug response, baseline response
and cut-off value, respectively. Raw data from nociceptive tests
were converted to AUC, calculated by the trapezoidal rule, at
specific time points. Statistical analysis of the in vivo timeecourse
curves was conducted by two-way or one-way ANOVA followed
by the Bonferroni’s post-test, unless otherwise stated. Whereas
corresponding AUC data were analyzed using one-way ANOVA
followed by the Dunnett’s post hoc test. Differences in values were
considered significant at *P < 0.05, **P < 0.01 and
***P < 0.001.23 in promoting [35S]GTPgS binding (see text for details).
Efficacy (Emax), stimulationSEM (%)
over the basal
ceptor
effect
Opioid receptor
mediated effect
NTS1 receptor
mediated effect
Brain Spinal cord
146.9  4.725 98.6  5.0 N/A
.20 (3.31)8 N/A N/A 146.6  0.038
.16 (113) 110.5  2.5 53.7  7.2 104.4  6.5
Figure 1 Time- and dose-dependent analgesic effect induced by (A) i.c.v., (B) i.t., and (C) i.p., and (D) i.v. PK23 administration. The analgesic
effect of a single bolus administration of PK23 in rats was measured with the tail-flick test. Doseeresponse curves derived from AUC calculated
after PK23 treatment are presented as insert within each panel. Individual data were compared to the control group injected with saline. Results
were analysed either with two-way ANOVA followed by Bonferroni’s post-test (doseeresponse curves) or one-way ANOVA followed by
Dunnett’s post hoc test (AUC calculation). Significant differences between animals receiving PK23 and control groups were indicated as:
*P < 0.05, **P < 0.01 and ***P < 0.001, respectively. n Z 6e7 rats/group. F4,120 Z 44.89 (P < 0.0001) and F4,30 Z 10.26 (P < 0.0001) for
i.c.v. administration; F4,120 Z 279.23 (P < 0.0001) and F4,30 Z 118.70 (P < 0.0001) for i.t. administration; F4,72 Z 4.70 (P Z 0.0020) and
F2,18 Z 6.34 (P Z 0.0082) for i.p. injection, and F4,80 Z 151.02 (P < 0.0001) and F3,20 Z 76.01 (P < 0.0001) for i.v. administration.
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Figure 2 Comparison of the antinociceptive effect mediated by i.t.
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MPE measured by the tail-flick test. ED50 values were calculated
using either the linear regression method (i.v. drug administration)
or nonlinear sigmoidal dose response (i.t. drug administration).
Differences in ED50 values for tolerance study were considered
significant when confience intervals did not overlap.
Cardiovascular and respiratory parameters were expressed as
means  SEM. Non-parametric U ManneWhitney test was used
for the comparisons of parameters between PK23 and saline
treatments, while the Wilcoxon’s signed-ranks test was used for
comparisons within groups. A P < 0.05 was considered statisti-
cally significant.administered PK23 (10 nmol/rat) and morphine (10 nmol/rat) as the
response to noxious thermal stimuli (Tail-flick test). Two-way
ANOVA followed by the Bonferroni’s post-test revealed significant
differences between PK23 vs. morphine (***P < 0.001), morphine vs.
control ($$$P < 0.001) and PK23 vs. control (###P < 0.001); n Z 7
rats/group. F4,72 Z 118.49 (P < 0.0001) and F2,18 Z 224.51
(P < 0.0001).3. Results
3.1. PK23 stimulation of opioid and NTS1 receptors
The effect of PK23 on the G protein activation efficacy (Emax) and
potency (pEC50) was tested in [
35S]GTPgS binding assays in
comparison with morphine and NT (Table 1). Analyses of
concentrationeresponse curves from data obtained both in spinal
cord or brain samples permitted to derive pEC50 values supportive
for an interaction of PK23 with both types of receptors tested.
Importantly, similarly to morphine, the potency and efficacy of
this chimeric peptide at m-opioid receptors appeared greater in
brain than spinal cord homogenates.
3.2. Dose- and time-dependent antinociceptive response
induced by PK23
In the radiant heat tail-flick test, PK23 exhibited a time- and dose-
dependent analgesic effect after supraspinal (i.c.v.), spinal (i.t.)
and peripheral (i.v.) administration (Fig. 1). Since ED50 represents
a dose required to achieve 50% of the maximal effect, there was
no posibility to produce the ED50 value for i.c.v PK23. This
resulted from the fact that higher doses generated serious adverse
effect that did not allow further testing, while lower shown less
that 50% activity; although for PK23 (i.t.) the ED50 value was 4.38
nmol/rat (i.t.). The maximal efficacy of PK23 was obtained after
i.t. administration (Fig. 1B). A strong pain-relieving effect, with
the MPE (%) value of 93.20  2.65%, was obtained 30 min-post-
injection with the highest PK23 dose tested (10 nmol/rat). The
response to PK23 was transient as the post-treatment MPE (%)
values reached baseline at 90 min after administration. On the
contrary, the weakest activity was observed in rats receiving an i.p.
administration of PK23 (Fig. 1C). Unexpectedly, whilst the lower
dose of 10 mg/kg resulted in a modest analgesic effect [MPE
(%) Z 9.45  0.81%] seen in the first 30 min post-administration,
a trend for increased pain sensitivity was observed when injected
at a dose of 15 mg/kg. The responses at both doses were calculated
to be statistically significant at 15 min (P < 0.01), 30 min
(P < 0.001) and 60 min (P < 0.001), respectively [data not shown
in Fig. 1; F4,48 Z 9.21 (P < 0.0001) and F1,12 Z 50.50
(P < 0.0001)].
PK23 also induced a modest antinociceptive effect in the tail-
flick test following i.c.v. administration (Fig. 1A). In fact,
maximal analgesia was obtained with a dose of 10 nmol/rat and
reached MPE (%) values of 15.79  1.41% (30 min post-
administration). However, central administration of PK23 at thisdose resulted in visible abnormalities of motor behavior man-
ifested by short barrel rotation.
Intrathecal administration of 10 nmol/rat of PK23 produced a
comparable analgesic effect as an equimolar dose of morphine
(Fig. 2). However, these similarities in terms of response magnitude
were observed only at 15 min [MPE (%) Z 84.50  3.84% for
morphine and MPE (%) Z 80.71  4.11% for PK23] and 30 min
post-administration [MPE (%) Z 86.23  4.76% for morphine and
MPE (%)Z 93.20  2.65% for PK23]. A noticeable and significant
attenuation of PK23-induced effect in comparison to morphine was
noticed at later time points (P < 0.001).
Intravenous (i.v.) PK23 administration revealed that this
compound could also induce a dose-dependent antinociceptive
response (ED50 Z 2.33 mg/kg) as measured by the tail-flick assay.
The maximal possible effect was observed for the 5 mg/kg dose
(Fig. 1D) at the 5 min time point with an MPE (%) value equal to
73.55  4.69%. After this time, the pain-relieving effect (practi-
cally for every dose tested) decreased dramatically.
3.3. Contribution of opioid and NT receptors to PK23-mediated
spinal analgesia
Animals were pre-injected with specific competitive antagonists
of opioid receptors (NTX), the NTS1 (SR48692) or NTS2 re-
ceptors (NTRC 824) in order to delineate the involvement of these
molecular targets in the effect of PK23. Pharmacological blockade
of the m-opioid and NTS1 receptors was found to significantly
attenuate the analgesic effect obtained with i.t. PK23 (Fig. 3).
Thus, injection of NTX (26.4 nmol/rat) considerably reduced the
analgesic response evoked by PK23 throughout the 120 min
observation period with maximal inhibition after 15 min [from
MPE (%) Z 80.71  4.11% for PK23 alone to MPE
(%) Z 12.12  1.89% observed after co-administration with
NTX] and 30 min [from MPE (%) Z 93.20  2.65% for PK23
alone to MPE (%) Z 21.95  2.94% observed after co-
administration with NTX]. Similarly, administration of SR
48692 resulted in an inhibition of the PK23 pain-relieving effect at
both 15 min [up to MPE (%)Z 53.36  2.99%] and 30 min [up to
MPE (%) Z 55.90  5.71%] post-injection, respectively. In fact,
Figure 3 Effect of the non-selective opioid receptor antagonist NTX (26.4 nmol/rat) and the selective NTS1 and NTS2 receptor antagonists: SR
48692 (17 nmol/rat) and NTRC 824 (17.5 nmol/rat), respectively, on the analgesic effect of PK23 (10 nmol/rat). Antagonists were administered
i.t. 10 min before PK23 and the response to the thermal stimulus was measured at different time points (panel A). Data from panel A were
combined allowing estimate inhibition as AUC values (panel B). Results were analyzed by two-way ANOVA (panel A) or one-way ANOVA
(panel B), revealing significant differences between PK23 alone and antagonist pre-treated PK23 groups. ***P < 0.001 (PK23 vs. PK23 þ NTX
and vs. PK23 þ SR 48692). From the panel BeDunnett’s post-test showed significances between PK23 and its combination with
NTX (P < 0.001) and PK23 vs. PK23 þ SR 48692 (P < 0.05); n Z 7 rats/group. F4,96 Z 239.84 (P < 0.0001) and F3,24 Z 22.56 (P < 0.0001)
for panel A.
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between timeecourse curves and AUC values for PK23 alone or
PK23 with NTX and SR 48692, respectively (Fig. 3A and B). In
contrast, NTRC 824 (17.5 nmol/rat) did not influence the anal-
gesic response to PK23 (P > 0.05). Estimation of the AUC for
NTRC 824 with PK23 indeed confirmed the absence of inhibition,
suggesting the lack of involvement of NTS2 receptor.
3.4. Assessment of the occurrence of tolerance following
administration of PK23
3.4.1. Tolerance development
Repeated i.t. administration of the chimeric compound PK23 for 8
consecutive days was performed in order to determine whether
PK23-induced effects would decline over time as a consequenceFigure 4 Dosee (A) and timeeresponse (B) curves of PK23 and morph
A: the doseeresponse relationship was examined on day 1 for both drugs a
were administered at the dose range of 0.5e10 nmol/rat. Panel B: Drugs we
days, and the effect was measured at 30 min time-point. Data are presented
way ANOVA (panel B) showed significant differences between PK23 and
**P < 0.01 and ***P < 0.001; post-hoc) and between morphine and contro
group. Asterisk (*) represents the ED50 value for morphine which was calc
of morphine was not able to induce antinociception equal 50% of the max
dependency; n Z 7 rats/group. F8,144 Z 171.89 (P < 0.0001) and F2,18 Zof tolerance. Although tolerance developed, likely resulting from
the activity of the opioid pharmacophore moiety, the loss of PK23-
induced analgesia was induced at a slower rate than for morphine
administered at the same dose of 10 nmol/rat (Fig. 4B). In fact, on
day 8 while the MPE (%) value calculated for PK23 was estimated
at 35.73  5.16%, the MPE (%) for morphine was
16.89  1.52%, reflecting the development of hyperalgesia
(Fig. 4B). Additionally, intrathecal PK23 chimera or morphine
was reported to exert different pharmacological actions mediated
by variations in receptor interactions.
Differences in tolerance development between tested drugs
were supported by the shifts in ED50 (with 95% CI), based upon
peak doseeresponse relationship values, and was shown in Table
2. Indeed, a repeated morphine treatment produced a 3.2-fold
increase in the acute ED50 values in the tail-flick test reflectingine following intrathecal (i.t.) administration in the tail-flick test. Panel
nd on day 3 (for morphine) or 4 (for PK23), respectively. Compounds
re intrathecally administered at a dose of 10 nmol/rat for 8 consecutive
as the percentage of maximum possible effect (MPE, %)SEM. Two-
morphine (###P < 0.001; post-hoc), PK23 and control (*P < 0.05,
l ($P < 0.05, $$P < 0.01 and $$$P < 0.001; post-hoc); n Z 6e10 rats/
ulated for the effect observed in days 1 and 3. The dose of 10 nmol/rat
imum effect. Administration of higher doses resulted in loss of dose-
415.68 (P < 0.0001) for panel B.
Table 2 ED50 values for morphine and PK23 analgesia in the rat tail-flick test after repeated intrathecal treatment.
Group ED50 vaule (nmol, i.t.)
a Shift
PK23 Day 1 Day 4 1.22*
4.38 (3.86e4.96) 5.36 (4.67e6.17)
Morphine Day 1 Day 3 3.20
2.82 (2.33e3.41) 9.03 (7.03e11.61)
The ED50 values were calculated from doseeresponse curve. For morphine-treated group, doseeresponse curve should have been generated
following 3 days treatment period due to the serious side effects (e.g., hyperalgesia) revealing in further days of administration and resulting in lack
of dose-dependent effect. *Statistically insignificant.
aMean (CI 95%).
1448 Karolina Frączek et al.a significant loss of analgesic potency. In the contrary, chronic
treatment of a tested hybrid resulted only in 1.22-fold increase of
the morphine ED50 values. Thus, development of tolerance to
intrathecal PK23 seems to be delayed as compared with morphine.
In the study of cross-tolerance, animals treated for 8 consec-
utive days with PK23 were found to retain analgesic response to
single injection of morphine (i.t.) on day 9 compared with the
saline-treated group. In these conditions, the magnitude of the
response to morphine [MPE (%) Z 33.10  5.44%] was
decreased compared to day 1 and was similar to the response to
PK23 alone measured on day 8 [MPE (%) Z 35.73  5.16%]
(Fig. 5A). Similarly, in an analogous study (Fig. 5B), adminis-
tration of PK23 on day 9 neither stopped nor reduced/improved
hyperalgesia induced by morphine (day 8, i.t.). The MPE value
were 6.89  1.52% vs. 14.38  2.71%, respectively. These
suggest the existence of cross-tolerance between PK23 and
morphine.3.4.2. Locomotor impairment
As shown in Fig. 6, rats having received 10 nmol/rat of PK23 (i.t.)
did not exhibit any impairment of motor activity. Furthermore,
when compared with morphine, significant differences appeared
during the entire testing period (*P < 0.05, **P < 0.01 and
***P < 0.001). In fact, at 30 min after administration, the latency
to fall was reduced from 286.50  4.39 s (for PK23) to
222.33  8.44 s (for morphine, respectively; F2,15 Z 10.44,
P Z 0.0014).3.4.3. PK23 induces less scratching and grooming behaviour
The PK23 hybrid peptide was found to elicit time-dependent
scratching and grooming behaviours in rats (Fig. 7AeD). How-
ever, at a dose of 10 nmol/rat i.t., the number of grooming events
induced by the chimeric compound was significantly lower as
compared to morphine-treated rats either on day 1 (F2,15 Z 13.54,
P Z 0.0004) or day 9 (F2,15 Z 26.79, P < 0.0001; Fig. 7A and C,
respectively). Similarly, on day 9, there was a notable difference in
the scratching response elicited by both drugs examined (Fig. 7D).
Indeed, within the first 30 min post-injection, morphine was found
to produce a strong scratch reflex in rats that weakened over time.
In contrast, PK23-treated animals demonstrated a time-dependent
increase in scratching behaviour (Fig. 7D). Noticeably, by the end
of the experiment (20e30 min post-administration), there were no
significant differences in such behaviours between animals
receiving either morphine or PK23 (P > 0.05). It’s worth
mentioning that morphine-treated rats also exhibited additional
behaviours that were merely absent in PK23-treated rats. These
included wet-dog shakes and teeth chattering.3.5. Cardiovascular and respiratory effects induced by
intrathecal PK23
Blood pressure and respiratory function in the PK23-treated group
(10 nmol/rat, i.t) was compared with saline-treated rats. As pre-
sented in Table 3, no changes in ventilation or heart rate were
reported after i.t administration of PK23. A visible, but insignifi-
cant decrease in arterial blood pressure (MAP) was noted imme-
diately after injection that lasted for 30 s. At 1 min, the depressor
response translated into an insignificant increase in MAP lasting
about 5 min. MAP values returned to baseline within 10 min.
3.6. Stability of PK23 in rat plasma in vitro and bloodebrain
barrier permeability after i.v. administration
Plasma stability of PK23 was evaluated. The compound was not
fully metabolized within the total experiment time (24 h). The
peak representing PK23 was observed on BPC recorded in
negative ion mode throughout the experiment (Supporting
Information Fig. S1). Starting from 1 h incubation the occur-
rence of two peaks (A and B, in Fig. S1) in BPC was observed.
Compounds A and B are the metabolic products of PK23 pro-
duced by plasma protease activity. The tentative chemical struc-
tures of A and B were proposed in Supporting Information Fig. S2
(Supplementary file). Compound A is a product of leucine and
isoleucine cleavage at the C-end of PK23. Compound B was
proposed as PK23 after the loss of phenylalanine present at the N-
end of the investigated peptide.
Apart from plasma stability studies, also brain penetration of
PK23 was assessed in our studies. Indeed, after a single intrave-
nous administration at a dose of 5 mg/kg, the test chimera was
found to penetrate the BBB, which was determined by HPLC
experiments using brain homogenates (Supporting Information
Fig. S3B).
4. Discussion
This paper describes the biological activity of PK23, a novel
compound combining an opioid- and an NT-like pharmaco-
phores. The presented chimeric ligand was found to exert a
strong antinociceptive effect, but noticeably weaker in compar-
ison to a previously reported PK20 and [Ile9]PK20 opioideNT
hybrids8,12. Indeed, both PK20 and its analogue were shown to
induce substantial pain-relief at doses approximately 500-times
(0.02 nmol/rat; i.t.) and 100-times (0.1 nmol/rat; i.t.) lower
than PK23 administered via the same route. However, intrathecal
administration of PK20 at a dose higher than 10 nmol/rat led to
sudden death of animals (data not published). Similar results
were observed for our compound but administered
Figure 5 Panels A and B represent cross-tolerance of PK23 or morphine with morphine or PK23, respectively, administered on day 9.
Measurements of the nociceptive response to thermal stimuli were conducted daily (30 min post-treatment), except for day 1; day 1 reflects the
baseline value (measurements performed before drug administration). In panels A and B, asterisks (one-way ANOVAwith Bonferroni’s post-test)
indicate significant differences in the effect obtained between PK23 (day 1) vs. PK23 (day 8) (***P < 0.001; panel A), PK23 (day 1) vs.
PK23þmorphine (day 9) (***P < 0.001; panel A), morphine (day 1) vs. morphine (day 8) (***P < 0.001; panel B) and morphine (day 1) vs.
morphine þ PK23 (day 9) (***P < 0.001; panel B), respectively. No statistical differences were observed in case of morphine or PK23 (day 8) vs.
morphine þ PK23 or PK23þmorphine (day 9), respectively; n Z 7 rats/group. F4,34 Z 89.66 (P < 0.0001) for panel A and F4,34 Z 360.0
(P < 0.0001) for panel B.
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consequence did not allow us performing a doseresponse
analysis that would give a complete picture after its i.c.v.
administration. Despite the relatively modest analgesic efficacy,
data obtained with this new compound, however, provide
essential information regarding structure modifications crucial
for obtaining a potent analgesic with reduced side effects. In
fact, substitution of 20,60-dimethyltyrosine (Dmt) for the N-ter-
minal Tyr in opioid peptides (as in PK20 chimera) has recently
been shown as a promising tool for improving opioid receptor
affinity and biological activity. However, it was shown that
accordingly to the “message-address” concept26,27 of opioid li-
gands, the lack of modification of the Tyr1 residue (as in PK23)
that comprises the message component may still result in high
affinity towards the opioid receptor, but with improved safety
profile of the compound. Additionally, the attached modified
pharmacophore of NT(8e13) may serve as an address domain
which can modulate opioid peptide receptor selectivity, while
maintaining specific interactions with the NT receptor. Further-
more, it was noticed that PK23 shows structural homology withFigure 6 The effect of PK23 on locomotor activity in comparison
to morphine. Drugs were given i.t. at a dose of 10 nmol/rat. Significant
differences were shown for PK23 vs. morphine (*P < 0.05,
**P < 0.01 and ***P < 0.001; Bonferroni’s post-hoc test), PK23 vs.
control ($P < 0.05; post-hoc test) and morphine vs. control
(###P < 0.001; post-hoc test); n Z 6 rats/group. F3,45 Z 0.32
(PZ0.8144) and F2,15 Z 10.44 (P Z 0.0014).the amphibian skin opioid peptide dermorphin (Tyr-D-Ala-Phe-
Gly-Tyr-Pro-Ser-NH2), especially considering the first two N-
terminally located amino acid residues that are also shared
among all deltorphins. Moreover, this dipeptide fragment dif-
ferentiates PK23 from its analogue, [Ile9]PK20. However,
considering that Dmt incorporation within the N-terminal part of
opioids plays an essential role in conferring high affinity to m-
opioid receptors, the role and functional diversity of various D-
amino acids in position 2 of the sequence still remain contro-
versial28,29. Thus, the functionality of the specific D-amino acid
residue while preserving the subsequent amino acids requires
further examination. Nevertheless, the PK23-mediated pain-
reducing activity was strongly evidenced after spinal adminis-
tration (Figs. 1B and 2) suggesting that the main site of action of
this opioidNT hybrid peptide, is located at the spinal cord
level. In fact, both the i.p. as well as i.v. delivery of PK23 was
found to exert rather weak antinociceptive responses when
compared to its central administration (Fig. 1C and D, respec-
tively). However, although opioid-based ligands can produce
analgesic effect through peripheral mechanisms, particularly in
inflammatory state, one could assume their capacity to penetrate
the bloodebrain barrier. Indeed, brain uptake of PK23 following
its single intravenous administration (5 mg/kg) to rats was shown
in Fig. S3. Such a result seems to be intriguing sincedaccording
to the “Lipinski’s Rule of Five”dthe optimal compound’s mo-
lecular mass desired for its sufficient BBB penetration should
not exceed 400 Da; of note, the molecular weight of the PK23
chimera is equal 1273 Da. Nevertheless, further studies with
multiple dosing may be performed in order to determine the
potential of PK23 chimera to accumulate within the brain.
Apart from the analgesic effect, opioids and various opioid-
based compounds are well-known for their ability to induce clini-
cally significant side effects, in particular tolerance and dependence.
The hybrid approach is aimed particularly at developing improved
compounds with fewer or more discrete side effects. In 2016, we
demonstrated that the responses obtained after administration of an
opioid hybrid peptide or a combination of its pharmacophores are
different8. In particular, the hybrid which combines two distinct
activities in a single molecular entity, caused no impairments of
motor function. Similar results were later obtained for PK23
Figure 7 Comparison of grooming (left column) and scratching (right column) responses elicited by PK23 and morphine administered i.t. at a
dose of 10 nmol/rat on day 1 (panels A and B) and day 9 (panels C and D). Two-way ANOVA followed by Bonferroni’s post-test indicated
significant differences (*P < 0.05; **P<0.01; ***P<0.001) between control and drug-treated groups (morphine or PK23) and between PK23 and
morphine-treated animals (#P < 0.05; ###P< 0.001); n Z 6 rats/group. F2,30 Z 0.70 (P Z 0.5034) and F2,15 Z 13.54 (P Z 0.0004) for panel A;
F2,30 Z 0.64 (P Z 0.5626) and F2,15 Z 0.62 (P Z 0.5529) for panel B; F2,30 Z 3.69 (P Z 0.0368) and F2,15 Z 26.78 (P < 0.0001) for panel C
and F2,30 Z 0.09 (P Z 0.9131) and F2,15 Z 47.33 (P < 0.0001) for panel D.
1450 Karolina Frączek et al.(Fig. 6). Furthermore, the analgesic properties of this compound
were preserved for a longer period of time as compared with
morphine after subchronical administration (Fig. 4B). Importantly,
morphine induced a severe loss of analgesic activity as soon as 3
days after initiating treatment. This may result from the different
pharmacokinetic profiles of these two drugs. However, the mean
elimination half-life of morphine ranges from 1.5 to 3.4 h30, while
the half-life of PK23 reaches similar values (t1/2 at 3.13 h). However,
being an analogue of PK20 (t1/2Z 31.45 h), PK23was anticipated to
show similar of extended half-life values13. We also cannot exclude
the hypothesis that the biochemical pathways responsible for
termination of the compound actions and desensitization of func-
tional m-opioid receptors differ.
The development of opioid receptor ligands associated with
reduced tolerance is of major importance31. New ligands could be
considered as substitutes for classical opioids or could be used in
opioid rotation protocols to obtain a balance between pain control
and the intensity of adverse effects.Table 3 Cardiovascular and respiratory effects of i.t. injected PK23
Factor PK23
Baseline 0 min MAX 10 m
VE, (mL/min) 121  12 118  10 122  13 113
HR (beat/min) 436  24 439  24 435  31 418
MAP (mm Hg) 83  4 76  5 97  8 87 
VE, minute ventilation; HR, heart rate; MAP, mean arterial blood pressure
maximum value selected between 1 and 5 min after injection; n Z 5 for PThere is evidence for the role of dopamine D2 receptors in the
development of morphine tolerance as well as on some motor
behaviors32,33. The possible activation of this dopamine receptor
by PK23 was therefore examined in [35S]GTPgS binding assay in
transfected cells31. Dopamine produced a robust response
(Emax Z 140.92%), while PK23 stimulated G protein activation
with much lower efficacy (Emax Z 117.13%) (Kleczkowska and
Hermans, unpublished data). Even more convincing, while the
response to dopamine was considerably reduced in the presence of
domperidone, this dopamine receptor antagonist was without in-
fluence on the response to PK23. Although we did not further
address the mechanism of lower side effect liability of PK23,
some hypotheses explaining this phenomenon exist. Firstly, the
effect observed may result from the activity of the NT-like phar-
macophore, attachment of which could have resulted in the
reduction of potency and selectivity of the compound to the m-
opioid receptors. Such a phenomenon reflecting changes in the
aforementioned features of a hybrid compound in comparison to a.
NaCl
in Baseline 0 min MAX 10 min
 14 120  8 119  9 124  5 120  7
 32 404  33 403  32 415  33 411  36
7 83  5 83  6 87  6 84  7
; Baseline, before injection, 0 min, early phase after injection, MAX,
K23 and n Z 4 for NaCl treated rats.
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kowska et al8. Secondly, this effect may be due to some putative
activity of PK23 at d-opioid receptors. The involvement of this
type of receptors in the development of opioid tolerance was
confirmed in transgenic d-opioid receptor knock-out mice34.
Hence, d-opioid antagonists were found effective in preventing
morphine tolerance35. It is possible that with a putative mixed m/
d activity, PK23 could modulate opioid receptor-mediated toler-
ance and dependence.
PK23-mediated antinociception and sustained pain-relieving
effect after repeated administration could also be the consequence
of its functional interaction with other nociceptive systems.
Indeed, animals treated with doses higher than 10 nmol (i.c.v.) of
PK23 exhibited behaviors such as barrel rotation, which are
related neither to opioid nor NT receptors. Also, death occurred in
some cases. Blockage of the b-adrenergic receptor was found to
exert antinociceptive effects and thus could represent a potential
target for PK2336.
Apart from the hallmark features of opioids, like tolerance and
dependence liability, NT is also known to elicit side effects like
anorexia nervosa37,38 or hypotension39. In our study, we did not
observe reduced food intake or changes in the body temperature
(data not shown) following subchronic i.t. administration of PK23.
Additionally, PK23 affected neither the respiratory system nor
induce hypotension. However, considering that the biological ac-
tivity of PK23 resulted rather from the synergistic interactions
between both of its pharmacophores, and given a strong involve-
ment of the NTS1 receptor agonist activity, we expected this
peptide to alter blood pressure. However, a single i.t. injection of
PK23 in anaesthetized animals did not significantly change either
blood pressure, heart rate or ventilation. What is more important,
by careful dose titration and the right selection of the delivery
route, we managed to avoid a prolonged hypotensive response
described previously after i.t and i.v. administration of neurotensin
(NT)39e41.
Several studies have reported that morphine elicits scratching
and grooming behaviours in rodents, together with a series of
other spontaneous signs accompanying nociceptive responses42,43.
In contrast, NT suppresses both grooming and scratching behav-
iour induced by several endogenous peptides, including b-endor-
phins and bombesin44,45. Such observations are highly consistent
with our data (Fig. 7). In fact, PK23 chimera was found to reduce
or delay grooming and scratching behaviours, which could be
explained by the presence of an NT-like structural component.
Whilst morphine significantly increased the scratching reflex in
rats, especially on day 9 (Fig. 7C), the effect induced by the tested
peptide was almost similar to that observed for control. This
however, was true only for the first 20 min post-administration as a
similar response to PK23 and morphine occurred at later time
points (between 20 and 30 min). Furthermore, attenuation of
grooming behaviour reported for i.t. administered PK23 chimera
(Fig. 7B and D) was also observed in our current study (in a
substance P-induced grooming model; data not shown). These
results clearly show that the C-terminal NT-like fragment is
strongly involved not only in the antinociceptive activity exhibited
by the chimera, but also in other of its properties.5. Conclusions
The herein presented that the opioideNT bivalent compound
PK23 seems a promising analgesic with a favourable profile interms of side effects, like reduced scratch reflex, delayed devel-
opment of tolerance and no obvious signs of motor impairment
when compared with the gold standard, morphine. However,
numerous additional studies need to be performed in order to
determine the possible mechanism of action of this novel chimera.
Furthermore, extended characterization of the analgesic and
possible side effects exerted by PK23 need to be performed to get
a complete picture of the compound’s activity.
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